Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 23 Feb 2026 | Laurent Muschel Director | Discussion on medical countermeasures developed by Osivax | — |
| 23 Feb 2026 | Laurent Muschel Director | Discussion on medical countermeasures developed by Osivax | SRC |
Mission & Goals
Osivax is a European clinical-stage biotechnology company pioneering universal influenza vaccine development through a groundbreaking T-cell-targeted approach. Our flagship vaccine candidate, OVX836, represents a paradigm shift in influenza prevention by targeting the highly conserved nucleoprotein across all influenza A strains, including pandemic variants. We have completed 7 clinical trials including 5 in Europe, with an additional large-scale Phase 2b efficacy trial currently ongoing across 16 clinical sites in France, Belgium, Germany, and Finland which is set to include 2850 participants by the end of 2025. Osivax is headquartered in Lyon, France, with an additional operational site in Liège, Belgium, we employ approximately 50 highly qualified professionals specialized in R&D, CMC, clinical development, regulatory affairs, and quality management.
EU Legislative Interests
Participation at the Joint Industrial Cooperation Forum on industrial preparedness for future health crises
Communication Activities
Parcitipation at the HERA Industry Days 2025
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Lyonbiopôle : https://lyonbiopole.com/en France Biotech : https://france-biotech.fr/ Biowin : https://www.biowin.org/
Organisation Members
Strategic partnerships with other leaders: https://osivax.com/about-us/#partners Osivax SAS (Osivax France) owns 100% of the shares of its two affiliates : - Osivax Belgique SRL located Bâtiment B 7 Rue des Chasseurs Ardennais 4031 Angleur - OSIVAX AUSTRALIA PTY LTD located SUITE 7 LEVEL 7, 330 COLLINS STREET, MELBOURNE VIC 3000
Connected Legislation
Mental health
Resolution on Taiwan (56th World Health Assembly)
Public health community action programme (2001-2006)
Pandemic influenza preparedness and response planning
Prevention of injury and promotion of safety
Health data and indicators, to provide information back-up (cancer, AIDS, etc.)
Public exposure limits to electromagnetic fields (0Hz-300Hz)
Mental Health
Mental Health
Mental health
EU Health Emergency Preparedness and Response Authority
European Health Insurance Card
Extension of EU public health action programmes
Mental health
Antimicrobials reserved for human infections
Summer-time arrangements
Injury prevention (action in the field of public health)
Community health action programme (2007-2013)
Health concerns associated with electromagnetic fields
Taiwan's observer status at the World Health Assembly (2002)
Mental health for the European Union